Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis
NCT ID: NCT07261306
Last Updated: 2025-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
EARLY_PHASE1
75 participants
INTERVENTIONAL
2025-08-29
2025-12-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Systemic Treatment Options for Generalized Lichen Planus
NCT06739551
Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis
NCT01710046
To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital
NCT07337434
Topical 1% Methotrexate Gel Versus Clobetasol Propionate in Patients With Psoriasis
NCT06555497
A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis
NCT03895372
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group mTX
Methotrexate is a modified antirheumatic drug work by inhibiting dihydrofolate reductase
Methotrexate
Methotrexate is an antifolate drug work by inhibiting enzyme dihydrofolate reductase and inhibit cell proliferation and play a role in psoriasis treatment
Tofacitinib
Tofacitinib is janus kinase inhibitor and had a role in treatment of psoriasis and psoriatic arthritis
Tofacitinib
Tofacitinib is janus kinase inhibitor and have role in psoriasis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methotrexate
Methotrexate is an antifolate drug work by inhibiting enzyme dihydrofolate reductase and inhibit cell proliferation and play a role in psoriasis treatment
Tofacitinib
Tofacitinib is janus kinase inhibitor and have role in psoriasis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Only patients with Psoriasis Area and Severity Index (PASI) score of 10 or above, and/or Body Surface Area (BSA) involvement of 10% or more, will be included.
* Duration of plaque psoriasis for at least 6 months prior to the study.
* Psoriasis that has not shown adequate response to topical therapies
Exclusion Criteria
* Participants currently receiving systemic corticosteroids, biologics, or any other immunosuppressive agents within 4 weeks prior to the start of the study will be excluded.
* Known hypersensitivity or contraindications to either methotrexate or tofacitinib.
* History of significant liver, kidney, hematologic/bleeding disorder, gastrointestinal/acid peptic disease, or immune system disorders.and any history of tuberculosis and malignancy.
* Pregnant or lactating women will not be eligible for the study.
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lahore General Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maryam Fatima
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maryam Fatima
Role: PRINCIPAL_INVESTIGATOR
Lahore General Hospital, Lahore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lahore general hospital
Lahore, Punjab Province, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Derma LGH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.